Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antifungal susceptibility testing methods.

M A Pfaller1

  • 1Molecular Epidemiology and Fungus Testing Laboratory, Section of Medical Microbiology, Department of Pathology, Carver College of Medicine, College of Public Health, University of Iowa, Iowa City, IW 52242, USA. michael-pfaller@uiowa.edu

Current Drug Targets
|December 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

Journal of clinical microbiology·2009
Same author

Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

Journal of clinical microbiology·2009
Same author

In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.

Journal of clinical microbiology·2009
Same author

In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Journal of clinical microbiology·2009
Same author

Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.

Journal of clinical microbiology·2009
Same author

Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Postgraduate medicine·2009
Same journal

Extracellular Vesicles from Mesenchymal Stem Cells Alleviate Spinal Cord Injury via the miR-486-5p/PTEN/PI3K/AKT Pathway.

Current drug targets·2026
Same journal

Improving B-cell Linear Epitope Prediction <i>via</i> Multiple Feature Fusion and an Integrated Machine Learning Algorithm.

Current drug targets·2026
Same journal

Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis.

Current drug targets·2026
Same journal

Epitranscriptomics in Breast Cancer: The Unveiled Role of RNA Modifications.

Current drug targets·2026
Same journal

Neuroinflammation in Alzheimer's Disease: New Approaches.

Current drug targets·2026
Same journal

FXYD3: A Key Regulator of Ion Homeostasis and Redox Balance in Cancer Biology.

Current drug targets·2026
See all related articles

New antifungal drugs combat invasive fungal infections, but understanding their action and resistance mechanisms is crucial. Standardized antifungal susceptibility testing aids management, with ongoing research optimizing methods for new agents and pathogens.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive mycoses present a significant clinical challenge, necessitating new systemic antifungal agents.
  • The increasing prevalence of invasive fungal infections drives the development of novel antifungal therapies.

Purpose of the Study:

  • To highlight the importance of understanding antifungal mechanisms of action and resistance.
  • To emphasize the role of standardized antifungal susceptibility testing in managing invasive mycoses.
  • To identify areas for future research in antifungal drug development and testing.

Main Methods:

  • Review of recent advancements in systemic antifungal agents.
  • Discussion of standardized antifungal susceptibility testing methodologies.

Related Experiment Videos

  • Analysis of challenges in current antifungal research and clinical practice.

    • Main Results:

    • A growing arsenal of systemic antifungal agents is available.
    • Antifungal susceptibility testing is a refined and valuable tool for managing invasive fungal infections.
    • Further research is required to elucidate drug mechanisms and resistance patterns.

    Conclusions:

    • Continued research into antifungal mechanisms of action and resistance is essential.
    • Optimization of antifungal susceptibility testing methods is needed for new agents and non-Candida pathogens.
    • International collaborations are vital for advancing the management of serious fungal infections.